Another NICE no for Glivec
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, will not be recommending Novartis's Glivec (imatnib) in high doses for patients with unresectable and/or metastatic gastrointestinal stromal tumours (GIST) because of a lack of data. The institute has issued final draft guidance to this effect today.